Literature DB >> 16945255

Pharmacologic treatment of migraine.

Marcy E Yonker1.   

Abstract

Nonsteroidal anti-inflammatory drugs are the mainstay of migraine treatment for children and adolescents by most primary care physicians. Not all patients respond to these readily available agents. Triptans have been studied in children and adolescents, and there is reasonable evidence to support the use of these agents in these populations. Other agents, such as combination preparations and ergot compounds, are also used in clinical practice, although there has been little scientific study. Prophylactic agents have been less well studied in those under 18 years of age. Agents such as antidepressants, anticonvulsants, and antihypertensives are commonly used in clinical practice. Safety issues are fairly well understood because of historical use and use for other conditions. Efficacy and optimal dosing have yet to be established for the treatment of migraine in children and adolescents in double-blind, randomized, placebo-controlled trials.

Entities:  

Mesh:

Year:  2006        PMID: 16945255     DOI: 10.1007/s11916-006-0063-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  23 in total

1.  A 40-year follow-up of school children with migraine.

Authors:  B Bille
Journal:  Cephalalgia       Date:  1997-06       Impact factor: 6.292

2.  Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?

Authors:  M L Hämäläinen; K Hoppu; P Santavuori
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

3.  Changes in the prevalence of migraine and other headaches during the first seven school years.

Authors:  M Sillanpää
Journal:  Headache       Date:  1983-01       Impact factor: 5.887

4.  A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.

Authors:  P Winner; A D Rothner; J Saper; R Nett; M Asgharnejad; A Laurenza; R Austin; M Peykamian
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

5.  Effectiveness of amitriptyline in the prophylactic management of childhood headaches.

Authors:  A D Hershey; S W Powers; A L Bentti; T J Degrauw
Journal:  Headache       Date:  2000 Jul-Aug       Impact factor: 5.887

Review 6.  Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.

Authors:  D Lewis; S Ashwal; A Hershey; D Hirtz; M Yonker; S Silberstein
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

7.  Migraine headaches in adolescents: a student population-based study in Monreale.

Authors:  V Raieli; D Raimondo; R Cammalleri; R Camarda
Journal:  Cephalalgia       Date:  1995-02       Impact factor: 6.292

8.  Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

Authors:  F Sorge; R De Simone; E Marano; M Nolano; G Orefice; P Carrieri
Journal:  Cephalalgia       Date:  1988-03       Impact factor: 6.292

9.  Children's ibuprofen suspension for the acute treatment of pediatric migraine.

Authors:  Donald W Lewis; David Kellstein; Georg Dahl; Bonnie Burke; L M Frank; S Toor; R S Northam; L W White; L Lawson
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

10.  Sodium valproate prophylaxis in childhood migraine.

Authors:  Gul Serdaroglu; Elvan Erhan; Hasan Tekgul; Figen Oksel; Serpil Erermis; Meltem Uyar; Sarenur Tutuncuoglu
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.